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ABSTRACT 
 
 
          BACKGROUND: Porphyromonas gingivalis (P. gingivalis) is a well-documented 
pathogen in chronic periodontitis, an inflammatory disease that results in the destruction 
of periodontal tissues. Kava, a compound extracted from the Piper methysticum plant, has 
been shown to have an anti-inflammatory effect in various systemic inflammatory 
diseases. The aim of this study was to assess the effects of a modified Kavain-derived 
compound, Kava-241, on periodontal destruction in a periodontitis-induced murine 
model. 
METHODS: The study involved 49 mice divided into three groups: control, diseased, and 
treatment. Diseased mice were infected with P. gingivalis via oral gavage and a type 2 
collaged antibody over a 15-day period to mimic periodontal infection. Treated mice 
received Kava-241 treatment before or after disease induction over the same 15-day 
period. Positive and negative control groups included mice that were diseased but 
received no treatment, and mice that received only treatment without P. gingivalis 
infection respectively. Bone loss and inflammatory cell activity was assessed by a 
morphometric analysis of the left mouse maxillae and a histomorphometric analysis of 
TRAP and H&E stained tissue sections of the right mouse maxillae. 
RESULTS: The P. gingivalis infected group showed significantly increased alveolar 
bone loss, inflammatory, and osteoclastic activity throughout the experimental period in 
comparison to the untreated control groups. The P. gingivalis-infected mice that received 
treatment with Kava-241 showed a significant decrease in inflammatory cell activity in 
periodontal connective tissues as compared to mice that did not receive any treatment. In 
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periodontal connective tissues, Kava-241 treated mice showed significant decreases of 
61.9% and 41.6% of polymorphonucleocyte and monocyte cell counts, respectively, 
compared to untreated mice. Furthermore, the mice that received treatment with 241 post-
infection showed a statistically significant decrease in alveolar bone loss. 
Histomorphometric analysis demonstrated 72.7% and 37.0% reductions of epithelial 
down-growth and bone loss respectively. Morphometric analysis demonstrated a 46.7% 
reduction of bone loss in treated mice compared to controls.A similar trend of reduction 
of osteoclastic activity was noted between the treated group and untreated group, 
however, this was not statistically significant. Mice pre-treated with 241 showed similar 
levels of bone loss and inflammatory cell activity as compared to those treated post-
infection. 
CONCLUSION: Our results demonstrate that in a murine model, P. gingivalis induced 
periodontitis can be treated by 241, a modified Kava compound. The experimental model 
demonstrated the use of morphometric and histomorphometric analyses to accurately 
quantify alveolar bone loss. Further modification of Kava could yield a more effective 
and safer therapeutic compound in the treatment of periodontal inflammation and bone 
loss.  
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CHAPTER ONE 
INTRODUCTION 
1.1. Periodontitis 
 Periodontitis, an inflammatory disease caused by bacterial plaque, is characterized 
by the destruction of the tooth supporting structure, involving epithelial downgrowth 
and  alveolar bone loss 1, 2. 
1.2. Pathogenesis of periodontitis 
The shift from a normal symbiotic microbiotic state to a dysbiotic state consisting 
of bacterial communities forming on subgingival tooth surfaces is the initial cause of 
peridontitis3, 4. The major periodontal pathogen associated with periodontitis is the 
gram-negative anaerobe, Porphyromonas gingivalis (P. gingivalis) 5, 6 There are 
many potential virulence factors and enzymes that could cause the pathogenicity of P. 
gingivalis, such as lipopolysaccharide, fimbriae, and various enzymes 7, 8. The 
initiation and progression of periodontitis are dependent on the mixed flora of plaque. 
Evidence shows that Aggregatibacter actinomycetemcomitans can pass through 
epithelial cells and into underlying connective tissue 9.  P. gingivalis can invade and 
persist in epithelial cells 10, 11. The breakdown of the antibacterial defense barrier and 
subsequent launch of periodontitis may be caused by bacterial leukotoxins that can 
kill neutrophils directly 12, 13.  However, bacterial infection is not the only cause of 
periodontitis; host susceptibility may play an important role in disease [23, 24]14, 15. 
The host response is variable among individuals and contributes significantly to the 
expression of periodontal diseases15. 
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1.3. Epidemiology 
Periodontitis is one of the most common chronic diseases in humans16. A recent 
epidemiolgical study of periodontal diseses estimated that 5–20% of the world’s 
population suffers from chronic periodontitis17. Periodontitis is a prevalent disease 
that affects >47% of US adults, 8.5% of them having its most severe form 18 .   
1.4. Systemic effect of periodontitis 
 The risk for atherosclerosis, diabetes, and adverse pregnancy could be impacted by 
periodontitis19-22. Furthermore, periodontitis has been associated with systemic 
diseases, such as cardiovascular complications23, rheumatoid arthritis24 , and 
Alzheimer’s disease25.  
1.5.  Immunology in periodontal disease 
Innate immunity is considered to act as a sentinel for the immune system and is 
immediately activated after recognition of the diverse range of microbial pathogens. 
Innate immune cells recognize signature molecules of microorganisms via various 
pattern recognition receptors (PRRs)26. Toll-like receptors (TLRs) are a well-
characterized class of PRRs in mammalian species 27, 28. TLRs can detect bacteria 
expressing various pathogen-associated molecular patterns (PAMPs)29. TLR2 can 
identify bacterial lipoproteins, peptidoglycans, and lipoteichoic acid 30; TLR4 can 
identify lipopolysaccharide (LPS) 31. LPS, lipoproteins, and fimbriae are surface 
components of P. gingivalis that interact with TLR2 and TLR4 expressed by host 
cells. This interaction stimulates the production of proinflammatory cytokines 32 such 
as interleukin-1B (IL-1B) , IL-6, -11, -17 and tumor necrosis factor alpha (TNF-
alpha). These proinflammatory cytokines are among a broad array of biomolecules 
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that have consistently been reported to be elevated in gingival crevicular fluid (GCF) 
andperiodontium of periodontitis patients33-38. In addition to the inflammatory 
response, an increased production of anti-inflammatory  cytokines 39, 40, such as IL-
10, and  receptor activator of NF-kB  ligand (RANKL), an osteoclast differentiation 
factor that promotes  osteoclastogenesis41, has been observed. The resultant 
osteoclastogenesis leads to the alveolar bone resporption observed in patients with 
periodontitis. In response, alveolar bone resorption occurs with increased 
osteoclastogenic activity leading to catabolism.  
Bone and tooth loss are the likely end result of the alveolar bone resorption 
observed in peridontitis. Bone loss results from the activation ofthe inflammatory 
process that promote interactions between the receptor activator of nuclear factor- 
kappa B (RANK), RANK ligand (RANKL), and the RANKL antagonist, 
osteoprotegerin (OPG) (Cochran 2008)37. These mediators are directly involved in 
osteoclastogenesis, activation, differentiation and  osteoclast survival 42-44. RANKL 
can mediate Periodontitis-related alveolar bone loss in vivo45, 46 . Given this 
interaction, it is possible that a RANK-RANKL/ OPG signalling pathway plays a 
significant role in mediating the alveolar bone loss observed in periodontal disease.  
Kavain has been found to inhibit LPS- induced TNF-α Factor (LITAF)-mediated 
TNF-α secretion both in vitro and in vivo in a murine model in which Kavain-treated 
mice were injected with lethal doses of LPS and found to be immune (Pollastri et al. 
2009).47 Prior in vivo studies have shown that P. gingivalis-induced bone loss resulted 
from a TLR2 and TNF-dependent macrophage-specific innate immune response to P. 
gingivalis infection 51. 
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1.6. Rheumatoid ARITHRITIS 
Rheumatoid arthritis (RA) is an autoimmune disease involving joint 
inflammation. RA has also been associated with systemic conditions such as  
cardiovascular disease. . The disease pathogenicity is due to an imbalance in 
inflammation-related cytokines, such as IL-1, IL-6, int-γ, and TNF-α. Current 
methods of diagnosing rheumatoid arthritis in patients by ACR and EULAR 
include four factors: the number of joints involved, the concentration of specific 
autoantibodies (RF and ACPA), the levels of general inflammation markers (C-
reactive protein and ECR), and the duration of the symptoms. These methods 
present with a significant error rate,  and an accurate method to identify the disease 
and its pathogenesis remains unknown. Furthermore, long-term treatment is 
unavaiable. In order to study the effects of RA, this study used a collagen-induced 
arthritis mouse model that closely mimics rheumatoid arthritis. 
 
1.7. 241 KAVA COMPOUND 
Kavain is a compound found in a beverage prepared from the roots of  Piper 
methysticum, originating in Polynesia and Micronesia. It has been  suggested to be 
responsible for the low incidence of cancer in natives of this island52 as well as its 
analgesic53 , relaxant54 , and anticonvulsant effects55. Recently, it was demonstrated 
that Kavain inhibits LITAF-mediated TNF-α secretion both in vitro and in vivo where 
Kavain-treated mice were immune to lethal doses of LPS, Given the immunity to 
lethal doses of LPS described earlier, Kavain can be said to be mediating TNF-α 
 5
suppression47.  Kava-derived compounds appear to be a promising anti-inflammatory 
agent that may also aid in the prevention and/or treatment of localized bone loss 
observed in periodontitis and in the joints affected by RA .  
 
1.8. Collagen antibody-induced arthritis (CAIA)  
The collagen antibody-induced arthritis (CAIA) murine model of 
rheumatoid arthritis can be used to identify pathogenic mechanisms and screen for 
potential therapeutic agents. To induce arthritis, a cocktail of monoclonal 
antibodies is given to the mice. These antibodies are directed to conserve auto-
antigenic epitopes in collagen type II and endotoxins. This CAIA model offers 
several key advantages which are lacking in the classic collagen-induced arthritis 
(CIA) model, including rapid disease onset, a high uptake rate, synchronicity, and 
the capacity to use genetically modified mice. This protocol takes 1–2 weeks to be 
completed.56 
 
1.9. Study Model 
Murine Murine models have been widely used to further understand the pathogenesis 
and theraputic modalities in periodontitis because the periodontal anatomy and the 
histopathology of periodontal diseases in mice are similar to those found in 
humans61.Several other benefits to use a murine model for studies of periodontitis 
includeknown genetics, controllable microflora, low cost, ease of handling, and a 
well- defined immune system.
62, 63
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The purpose of this study was to test the ability of Kavain to alleviate the  
symptoms of CAIA and  P. gingivalis- gavage-induced periodontitis in a murine 
model. Bone and connective tissues parameters were quantified and analyzed to 
determine the role of treatment and prevention in experimental periodontitis.  
 
1.10. Hypothesis 
 Periodontitis is an inflammatory disease caused by dysbiotic microbial  
infection, and Rheumatoid arthritis is an autoimmune disease that primarily causes 
 inflammation. Recent publications demonstrate that the Kava compound inhibits  
LITAF-mediated TNF-α secretion in vitro and in vivo. We hypothesize that a 
modified Kava-derived compounds may help to prevent or treat localized bone loss 
and inflammation observed in periodontitits and rheumatoid arthritis.  
 
1.11.  Objectives 
I. To evaluate the ability of a modified Kava compound in reducing the activity 
involved in the inflammatory process in a murine model of P. gingivalis-gavage-
induced periodontitis.and,  
II. To evaluate the ability of the modified Kava compound to alleviate the symptoms 
of CAIA in vivo in a murine model of RA.  
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CHAPTER TWO 
MATERIALS AND METHODS 
2.1.  Mice 
This study was carried out in a pathogen-free unit of the animal facility 
located at Boston University Medical Campus. To minimize any potential estrogen 
effects, only six-week-old, pathogen-free DBA1/BO male mice (Taconic Farm, 
Rensselaer, NY) were used. The mice were fed sterile food and distilled water ad 
libitum. All of the experimental procedures in this study were approved by the 
Institutional Animal Care and Use Committee at the Boston University Medical 
Center. 
2.2. Bacteria 
The specific P. gingivalis strain W83 was used (BAA-308; ATCC, Manassas, VA, 
USA). This pathogen was cultured and maintained in Schaedler anaerobe broth 
(Oxoid Ltd., Basingstoke, Hampshire, England), supplemented with hemin (5 μg/ml, 
Sigma-Aldrich, St. Louis, MO), menadione (1 μg/ml, Sigma-Aldrich, St. Louis, MO), 
and sodium bicarbonate (420 μg/ml, Sigma-Aldrich, St. Louis, MO) in an anaerobic 
chamber with 85% N2, 10% H2, and 5% CO2 at 37°C. Bacteria at early logarithmic-
phase growth were used for inoculation procedures. An average 5 × 108 colony- 
forming units of W83 (BAA-308; ATCC, Manassas, VA, USA) in 100 μl phosphate-
buffered saline with 2% carboxymethylcellulose (Sigma-Aldrich, St Louis, MO, 
USA). This was administered by oral gavage for 15 days.  
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Hemin solution 
25.0 mg Hemin 
0.5 ml 1M NaOH 
49.5 ml Distilled water 
The solution was mixed well and filtered with a sterile 0.22 μm filter. 
 
Menadione (Vitamin K) solution 
150.0 mg Menadione 
30.0 ml 95% Ethanol 
The solution was mixed well and filtered with a sterile 0.22 μm filter. 
 
4.2% Sodium Bicarbonate (NaHCO3) 
2.1 g NaHCO3 
50.0 ml Distilled water 
The solution was mixed well and filtered with a sterile 0.22 μm filter. 
 
Schaedler anaerobe broth 
14.2 g Schaedler anaerobe broth 
500.0 ml Distilled water 
The broth was autoclaved for 30 min at 121°C. 
The broth was cooled  to room temperature. 
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5 ml hemin and 100 μl menadione were added to 500 ml broth. 
 
2.3.  Induction of periodontitis lesion 
Forty-seven mice were randomly assigned to one of seven groups: a P. 
gingivalis-infected and antibody injected group (periodontitis)(positive control); a P. 
gingivalis-infected group, antibody injected and Kava compound treatment group; a 
P. gingivalis-infected, antibody injected and Kava compound prevention group; a P. 
gingivalis-infected only group; antibody only group; Kava compound treatment only 
group; and a Kava compound preventive only group. Mice were given 
sulfamethoxazole at 0.87 mg/ml and trimethoprim at 0.17 mg/ml ADD (Hi-Tech 
Pharmacal Co. Inc., Armityville, NY, USA) in milli-Q water ad libitum for 10 days, 
followed by 3 days without antibiotics. Mice in the P. gingivalis-infected group  were 
anesthetized with Isophrane and,  mice were inoculated with an average 5 × 108 
colony-forming units of P. gingivalis strain W83 (BAA-308; ATCC, Manassas, VA, 
USA) in 100 μl phosphate-buffered saline with 2% carboxymethylcellulose (Sigma-
Aldrich, St Louis, MO, USA) and were administered by oral gavage for 15 days. 
With an average 5 × 108 colony- forming units of P. gingivalis strain W83 (BAA-
308; ATCC, Manassas, VA, USA) in 100 μl phosphate-buffered saline with 2% 
carboxymethylcellulose (Sigma-Aldrich, St Louis, MO, USA) and was administered 
via oral topical application for a total of 15 inoculations. The non-P. gingivalis-
infected groups were anesthetized with Isophrane and inculated with 2% 
carboxymethylcellulose (Sigma-Aldrich, St Louis, MO, USA). This was administered 
by oral gavage for 15 days. Mice were euthanized by CO2 inhilation at scheduled 
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time points 15 days after gavage inculation. In histomorphometry: N=7 in each group; 
in morphometry: N=7 in each group and in cell counting: N=7 in each group. 
Isophrane 
0.74 ml Phosphate-buffer saline (PBS) 
0.16 ml Ketamine (100 mg/ml) 
0.10 ml Xylazine (20 mg/ml) 
 
Figure 1:Overview for experimentally induced periodontitis model 
 
2.4.  Induction of Arthritis lesion  
Forty seven mice were randomly assigned to one of seven groups: a P. gingivalis-
infected and antibody injected group (periodontitis); P. gingivalis-infected group; 
antibody injected and Kava compound treatment group; P. gingivalis-infected, 
antibody injected and Kava compound prevention group; P. gingivalis-infected only 
group, antibody only group; Kava compound treatment only group; and Kava 
compound preventive only group. Mice in the antibody injected group were 
Birth 6 weeks
old
8 weeks
old
Pre-
treatment
with
antibiotics
10 weeks
old
Group 1: P.gingivalis + AB
Group 2: P.gingivalis + AB + Kava-241 (treatment group)
Group 3: P.gingivalis + AB + Kava-241 (prevention group)
Group 4: P.gingivalis
Group 5: AB
Group 6: Kava-241(treatment)
Group 7: Kava-241 (prevention)
Experimental procedure (days)
1 2 3 54 6 7 8 9 10 11 12 13 14 15
Injection of P.gingivalis
Injection of Kava-241 (treatment group)
Injection of Kava-241 (prevention group)
-3 -1
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anesthetized with Isophrane and were intraperitoneally  injected  with 2 mg  of CAIA 
one day before the P.gingivalis oral gavage admenestration . 
2.5.  241 Kava Compound treatment and prevention 
Forty seven mice were randomly assigned to one of seven groups: a P. gingivalis-
infected and antibody injected group (periodontitis); P. gingivalis-infected group, 
antibody injected and Kava compound treatment group;  P. gingivalis-infected, 
antibody injected and Kava compound prevention group; P. gingivalis-infected only 
group; antibody only group; Kava compound treatment only group; and Kava 
compound preventive only group. Mice in the Kava treatment group were 
intraperitoneally injected with 40 mg/kg Kava compound on days 5, 8, 11 and 14 of 
the experiment. However, mice in the Kava prevention groups were intraperitoneally 
injected with two doses of 40 mg/kg Kava compound. The first dose was given three 
days before the P.gingivalis oral gavage admenestration. Followed by second dose 
one day before the P.gingivalis oral gavage admenestration followed by the following 
adminstration timing days 2, 6, 9, and 13 of the experiment.  
2.6. Tissue specimen preparation for periodontal analysis 
The palatal bone and intact surrounding tissue from each euthanized animal was 
dissected and fixed with 4% freshly prepared paraformaldehyde (Sigma-Aldrich, St. 
Louis, MO) in PBS (pH 7.2) for 24 hr at 4°C. After fixation, the specimens were 
consecutively washed with 5%, 10%, and 15% glycerol (American Bioanalytical, 
Natick, MA) in PBS, each for 15 min at 4°C, and decalcified in an 
Ethylenediaminetetraacetic Acid Tetrasodium Salt Dihydrate EDTA(Sigma-Aldrich, 
St. Louis, MO)for 14 days at 4°C. Once a day during this period, the specimens were 
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gently stirred and the solutions refreshed. The samples were then immersed in 30% 
sucrose (Sigma-Aldrich, St. Louis, MO) in PBS until embedding. The tissue block 
was embedded with a HISTO PREP® compound (Fisher Scientific, Hanover Park, IL) 
for cryostat sectioning. Serial mesiodistal sections (5 μm) parallel to the long axis of 
the teeth were made. The correctly oriented sections were stained with hematoxylin 
and eosin for histomorphometric analysis. 
 
Figure 2:Overviw of Periodontal Analysis 
2.7.  Hematoxylin and Eosin (H&E) stain 
The sections were fixed by immersing the slides in acetone (ACROS 
Organics, Morris Plains, NJ) for 5 min, then air drying them for 5 min at room 
temperature. The slides were rinsed for three times every 5 min in PBS to remove the 
tissue-freezing matrix, and then immersed in Hematoxalin solution (Fisher Scientific, 
Pit, IL) for 3 min. They were then washed with tap water for 3 min, fast-dipped in 
acid ethanol (Sigma-Aldrich, St. Louis, MO) 8 to 12 times, washed with tap water 
two times for 1 min, and then cleansed with de-ionized water for 2 min. The slides 
were then placed in an eosin solution (ACROS Organics, Morris Plains, NJ) for 30 
sec and dehydrated for 3 min in each solution of alcohol series: 95%, 95%, 95%, 
100%, 100%, and 100%. Finally, the slides were bathed in Xylene (Fisher Scientific, 
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Pit, IL) three times for 5 min and coverslipped with Permount (Fisher Scientific, Pit, 
IL). 
 
2.8.  Histomorphometric analysis 
Interdental areas between the first and second molars of the right maxillary 
quadrants were examined. The measurements included extension of the apical 
migration of epithelium (epithelial downgrowth) and bone resorption on H&E-stained 
sections from images captured at 100X magnification using an image analysis system 
(Image-Pro Plus Version 5.0, Media Cybernetics, Silver Spring, MD). Epithelial 
downgrowth was defined by measuring the distance from the cementoenamel junction 
(CEJ) to the apical extent of the junctional epithelium. Bone resorption was measured 
as the distance between the CEJ and the alveolar bone crest (ABC). Sections from 
different specimens were evaluated in a random sequence. The measurements were 
repeated 2 times per site, and the results were presented as the distances (µm). 
A minimum of 6 fields from each interdental area (from CEJ to root apex of the 
second molar) were analyzed. To ensure that the region examined represents the 
buccal-lingual midpoint, the analysis was done only for sections where the root canal 
systems of the adjacent teeth were visible and properly oriented. In each area of 
interest, the total number of inflammatory cells was counted manually from images 
captured at 400X magnification on H&E-stained sections. The inflammatory cells 
included polymorphonuclear neutrophils (PMN), mononuclear leukocytes, and 
fibroblasts; all were identified by their characteristic morphologies. The data were 
then reported as the number of each type of cell per mm2. 
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2.9.  Morphometric analysis 
The alveolar bone around the left maxillary second molars was measured by the 
morphometric method as previously described.64 The skulls were mechanically 
defleshed after 15 min of treatment in boiling water, washed with PBS, and then 
exposed overnight in 3% hydrogen peroxide. Next, they were washed with PBS three 
times for 5min, immersed in bleach for 1 min, washed again with PBS for three times 
for 5min, and then dried in an incubator at 37°C for 1 hr. The skulls were then stained 
at room temperature with 1% methylene blue (Sigma-Aldrich, St. Louis, MO) for 1 
min, after which, they were dried in an incubator for 30 min at 37°C. The 
measurement of distances from cemento-enamel junction (CEJ) to alveolar bone crest 
(ABC) were made under a dissecting microscope fitted with a video image marker 
measurement system (Image-Pro Plus version 6.0) standardized to give measurements 
in μm. The measurements were repeated 2 times per site. All measurements were 
made on images taken with the 3 molar teeth in the same occlusal plane.  
             The distance from the CEJ to the ABC was measured at 6 sites per tooth 
mesio-buccal (MB), mid-buccal (MidB), disto-buccal (DB), distopalatal (DP), 
midpalatal (MidP) and mesio-palatal (MP) was done with the assistance of an image 
analysis system.  
 
2.10. Osteoclast Activity Analysis 
Activity of osteoclasts along the alveolar bone crests were measured between first, 
second, and third molars in 5µm histological slices. Osteoclasts were detected by 
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staining for TRAP. 40mL of 0.2M Sodium Acetate buffer solution (pH 5.0) was 
mixed with 56mg of Fast Red Violet LB Salt, 38.8mg Tartaric Acid, and 160µL of 
10% MgCl2. In a separate container in an opaque container to block light. Then, 
6.4mg of Naphthol was mixed thoroughly with 0.4mL of N,N-dimethylformamide. 
The sodium acetate and naphthol solution were then mixed together. The solution was 
filtered through a 22µL filter into a new container that was also opaque. The solution 
was kept at 37⁰C before, during, and after staining slides. 5µm thick histological 
slides from mice were then exposed to the TRAP solution for 10 minutes at 37⁰C. 
The slides were then washed for 30 minutes before being counter-stained with 
hematoxilline for 5 seconds. Osteoclasts were identified as being positively stained 
for TRAP, present along the alveolar bone crest, possessing and possessing a ruffled 
border with an underlying lacunae. The number of osteoclasts present was determined 
by x400 magnification using image analysis software. Data are presented as the 
number of osteoclasts per µm of bone. 
 
2.11.  Statistical analysis 
All measurements were performed in a blind fashion and double-checked at 
a one-week interval. Intra-examiner variation was found to be less than 5%. All 
values were expressed as mean ± SEM. A two-tailed Student’s t-test for comparison 
between two groups. A P value of <0.05 was considered to be statistically significant. 
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CHAPTER THREE 
RESULTS 
3.1.  Epithelial downgrowth 
The apical migration of epithelium is a sign of the pathological progress of  
periodontitis. Epithelial downgrowth was measured by the distance of apical 
migration of epithelial attachment relative to the CEJ. The positive control (antibody 
and P.gingivalis) group exhibited the most epithelial downgrowth when  
compared with other groups. Mice in the antibody, P.gingivalis and Kava compound 
treatment and the antibody, P.gingivalis and Kava compound prevention groups 
exhibited significantly less epithelial downgrowth (72.7% and 84% respectively), 
when compared with positive control group (antibody and P.gingivalis)., The mice in 
the P.gingivalis-only  and antibody-only groups showed a statistically significant 
smaller epithelial downgrowth (61.1% and 86.2% respectively) when compared with 
the positive control group (antibody and P.gingivalis).. Mice in the antibody, 
P.gingivalis and Kava compound prevention group performed better than those in the 
antibody, P.gingivalis and Kava compound treatment group, particularly in regards to 
reducing epithelial downgrowth. Mice treated with the antibody only, Kava treatment 
only and Kava preventive only exhibited significantly less epithelial downgrowth , as 
compared with the positive control group (antibody and P.gingivalis) (86.3% and 
91.9% respectively). 
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Figure 3:Histomorphometric Analysis Epithelial Downgrowth and Bone Loss. 
 
Figure 4:Histomorphometric Epithelial Downgrowth graph. 
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Table 1: Histomorphometric Epithelial Downgrowth . 
 
3.2.  Alveolar Bone Loss Histomorphometry 
To assess alveolar bone loss, distances were measured from the CEJ to the ABC on 
histomorphometry sections. The positive control (antibody and P.gingivalis) group 
exhibited the highest amount of alveolar bone loss when compared with other groups. 
Mice in the antibody, P.gingivalis and Kava compound treatment group and the 
antibody, P.gingivalis and Kava compound prevention group exhibited significantly 
less alveolar bone loss (36.98% and 39.05% respectively) when compared with the 
positive control group.Mice in the P.gingivalis only  and antibody only groups 
showed statistically less alveolar bone loss (36.5% and 50.72% respectively) when 
compared with positive control group. This finding indicates that the combined effect 
of P. gingivalis and antibody is required in order to achieve maximum bone loss. 
Mice in the antibody, P.gingivalis and Kava compound prevention group showed a 
further decreased alveolar bone loss compared to those in the antibody, P.gingivalis 
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and Kava compound treatment group. Mice treated with the antibody only, Kava 
treatment only, or Kava preventive only exhibited significantly less alveolar bone loss 
compared with the positive control group (58.5% and 43.18%  respectively). 
 
Figure 5:Histomorphometric Bone Loss Graph. 
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Table 2: Histomorphometric Bone Loss. 
3.3. Alveolar Bone Loss Morphometry 
To measure alveolar bone loss, the distance from the CEJ to the ABC was 
measured at 6 sites per tooth mesio-buccal (MB), mid-buccal (MidB), disto-buccal 
(DB), distopalatal (DP), midpalatal (MidP) and mesio-palatal (MP) with the 
assistance of the Image Pro system. All measurements were made on images taken 
with the 3 molar teeth in the same occlusal plane. The positive control (antibody and 
P.gingivalis) group exhibited the highest amount of alveolar bone loss when 
compared with other groups. Mice in the antibody, P.gingivalis and Kava compound 
treatment group and the antibody, P.gingivalis and Kava compound prevention group 
exhibited significantly less alveolar bone loss (46.68% and 48.49% respectively), 
when compared with positive control (antibody and P.gingivalis) group. The mice in 
the P.gingivalis.only and antibody only groups showed a statistically significant 
lower amount of alveolar bone loss (22.07% and 40.15% respectively) when 
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compared with positive control group (antibody and P.gingivalis). This finding 
indicates that the combined effect of P.gingivalis and antibody is required to achieve 
maximum bone loss. Mice in the antibody, P.gingivalis and Kava compound 
prevention group showed a significantly greater decrease in alveolar bone loss than 
the antibody, P.gingivalis and Kava compound treatment group. The mice treated 
with the antibody only, Kava treatment only and Kava  preventive exhibited 
significantly less alveolar bone loss compared to the positive control group (antibody 
and P.gingivalis) (46.68% and 43.07% respectively). 
 
Figure 6:Morphometric Analysis 
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Figure 7: Morphometric Analysis Graph. 
 
 
Table 3:Morphometric Bone Loss 
3.4.  Presence of inflammatory cells in periodontitis 
          A minimum of 6 fields from each interdental area (from CEJ to root apex 
of the second molar) were analyzed. To ensure that the region examined represents 
the buccal-lingual midpoint, the analysis was done only for sections where the root 
canal systems of the adjacent teeth were visible and properly oriented. In each area of 
interest, the total number of inflammatory cells was counted manually from images 
captured at 400X magnification on H&E-stained sections. The inflammatory cells of 
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interest included polymorphonuclear neutrophils (PMN), mononuclear leukocytes, 
and fibroblasts; all were identified by their characteristic morphologies. The data 
were then reported as the number of each type of cell per µm2. The positive control 
(antibody and P.gingivalis) group exhibited the maximum amount of mononuclear 
leukocytes when compared with other groups. Mice in the antibody, P.gingivalis and 
Kava compound treatment group and the antibody, P.gingivalis and Kava compound 
prevention group exhibited significantly less mononuclear leukocytes  (41.58 % and 
62.01% respectively), when compared with positive control (antibody and 
P.gingivalis) group. The mice in the P.gingivalis.only and antibody only groups 
showed significantly fewer mononuclear leukocytes (39.9% and 80.28% respectively) 
when compared with positive control group (antibody and P.gingivalis). Mice in the 
antibody, P.gingivalis and Kava compound prevention group showed a significantly 
greater decrease in mononuclear leukocytes than the antibody, P.gingivalis and Kava 
compound treatment group. The mice treated with Kava treatment only and Kava 
preventive only exhibited significantly fewer mononuclear leukocytes compared to 
the positive control group (antibody and P.gingivalis) (78.36% and 72.35% 
respectively). 
 
Figure 8:Mononuclear Leukocytes Count. 
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Table 4:Mononuclear Leukocyte Count. 
 
The positive control (antibody and P.gingivalis) group exhibited the highest 
number of polymorphonuclear neutrophils (PMN) when compared with other groups. 
Mice in the antibody, P.gingivalis and Kava compound treatment group and the 
antibody, P.gingivalis and Kava compound prevention group exhibited significantly 
fewer mononuclear leukocytes  (61.96% and 67.35% respectively), when compared 
with positive control (antibody and P.gingivalis) group. The mice in the 
P.gingivalis.only and antibody only groups showed significantly fewer 
polymorphonuclear neutrophils (PMN) (61.24% and 81.65% respectively) when 
compared with positive control group (antibody and P.gingivalis). Mice in the 
antibody, P.gingivalis and Kava compound prevention group showed significantly 
greater decrease in mononuclear leukocytes than the antibody, P.gingivalis and Kava 
compound treatment group. The mice treated with Kava treatment only and Kava 
preventive only exhibited significantly fewer polymorphonuclear neutrophils (PMN) 
 29
compared to the positive control group (antibody and P.gingivalis) (84.97% and 
87.66% respectively). 
 
Figure 9: Polymorphonuclear Neutrophils Count 
 
 
Table 5:Polymorphneuclear Neutrophils 
3.5. Presence of fibroblast in periodontitis 
  The positive control (antibody and P.gingivalis) group exhibited the minimum 
amount of fibroblast when compared with other groups. Mice in the antibody, 
P.gingivalis and Kava compound treatment group and the antibody, P.gingivalis 
and Kava compound prevention group exhibited more fibroblasts (8.92 % and 
27.47% respectively), when compared with positive control (antibody and 
P.gingivalis) group. The mice in the P.gingivalis.only and antibody only groups 
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showed significantly more fibroblasts (16.17% and 33.72%) when compared with 
positive control group (antibody and P.gingivalis). The mice treated with Kava 
treatment only and Kava preventive exhibited significantly more fibroblast 
compared to the positive control group (antibody and P.gingivalis) (27.41% and 
33.22% respectively). 
 
Figure 10:Fibroblast Count. 
 
Table 6:Fibroblast Count. 
 
3.6. Presence of Osteoclastic Activity 
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 Osteoclastic activity showed a similar trend of reduction between the 
treatment group and the no-treatment group, however, this was not statistically 
significant. The positive control (antibody and P.gingivalis) group exhibited the 
highest amount of osteoclastic activity when compared with other groups. Mice in the 
antibody, P.gingivalis and Kava compound treatment group and the antibody, 
P.gingivalis and Kava compound prevention group exhibited less osteoclastic activity  
(56.3% and 25.5% respectively), when compared with positive control (antibody and 
P.gingivalis) group. The mice in the P.gingivalis.only and antibody only groups 
showed less osteoclastic activity (33.8% and 7%) when compared with positive 
control group (antibody and P.gingivalis). The mice treated with Kava treatment only 
and Kava preventive only exhibited less osteoclastic activity compared to the positive 
control group (antibody and P.gingivalis) (46.4% and 46.4% respectively) . 
 
 
 
 
 
CHAPTER FOUR 
DISCUSSION 
     In this study, P. gingivalis-oral gavage was successfully used to induce 
experimental periodontitis in mice. The results demonstrated site-specific, time- 
dependent epithelial downgrowth, alveolar bone loss, and inflammation in this model. 
The use of histomorphometric and morphometric analysis for charting the progression 
of periodontitis in this model was also confirmed. Both methods yielded comparable 
results for detecting alveolar bone loss. Moreover, the osteoclast activity observed in 
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this study was consistent with the progression of an inflammatory front as 
demonstrated in earlier studies using a monkey model 65.  
Several methods have been presented in the literature for inoculating periodontal 
pathogens into the oral cavity of experimental animals, including diet, ligature, and 
oral infection by gavage  61, 66, 67. Most methods demonstrated an obvious periodontal 
breakdown. However, the P. gingivalis-oral gavage approach provides a simple and 
direct method to deliver enough bacteria into the murine gingival sulcus to colonize 
and to initiate pathogenesis of periodontitis. In this study, the oral gavage was 
administered every day to maintain a constant specific bacterial infection. After 
infection, P. gingivalis was only recovered in the Kava treatment mice (14 days) and 
not recovered in untreated control mice. This data suggested P. gingivalis-oral gavage 
can successfully deliver P. gingivalis into mouse mouth and thereby contribute to the 
induction of experimental periodontitis.  For all these reasons, we elected to use P. 
gingivalis-oral gavage to promote alveolar bone loss in hopes of documenting a 
reproducible model of murine experimental periodontal disease approximating human 
periodontal disease.  
Inflammation was clearly induced in the infected group, as evidenced by the 
infiltration of leukocytes, especially PMNs, 14 days after administration of P. 
gingivalis- oral gavage. This is consistent with observations made in ferrets, dogs, 
rats, monkeys, and humans (6, 68-71. Periodontal tissue destruction increased with 
increasing experimental time and corresponded to obvious inflammatory infiltration. 
The number of osteoclasts around the alveolar bone surface also increased after 
infection. The inflammatory lesion was associated with numerous osteoclasts, 
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resulting in alveolar bone loss. Additionally, bone at the alveolar bone crest was 
rapidly resorbed by 14 days after the administration of P. gingivalis-oral gavage, 
findings that are consistent with the current literature in other models 72. Moreover, 
the periodontal destruction with bone resorption and epithelial downgrowth observed 
in the model used in this study was in agreement with data in monkeys, rodents, dogs, 
and humans 71, 73-75.The present finding indicates that the methods used in this study 
could cause rapidly destructive experimental periodontitis in mice.  
Histological analysis is an accurate and widely accepted technique for measuring 
alveolar bone loss 76-78. Although necessary tissue preparation steps require 
substantial effort, histological measurements can simultaneously provide alveolar 
bone loss quantification and other histology/immunohistochemistry measurements. 
Morphometric techniques are also widely used in measuring the alveolar bone loss in 
animal models of periodontitis 62, 79. This method is precise in measuring horizontal 
bone loss and is reproducible 61, 64. However, a disadvantage of morphometry is the 
need to remove soft tissues overlying the bone prior to making measurements 
In this study, evidence is presented that mice infected with P. gingivalis suffer severe 
inflammation and periodontal tissue breakdown leading to alveolar bone loss 
compatible with other known animal models of periodontal disease. The 
histomorphometric analytical approach is recommended because both soft and hard 
tissue is captured.  
The results of this study demonstrate that 241, a modified Kava in periodontitis 
resulted in a reduction of periodontal breakdown, inflammatory cell infiltrate, 
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osteoclastogenesis, and fibroblasts. These observations are consistent with a previous 
report using Kavain shows significantly reduced experimental 
 periodontal bone loss 80.  
An additional aim of this study was to evaluate the role 241, a modified Kava in the 
management of inflammatory lesions, given that an important feature of periodontitis 
is the inflammatory lesion preceding bone loss. The use of well-defined boxes helped 
capture the progression of inflammatory cell counts which showed gradual decrease, 
while steady increase for fibroblasts from superficial to deeper structures 
respectively. In all three regions, 241, a modified Kava significantly reduced the 
inflammatory infiltrate equally affecting PMN and mononuclear cells. These results 
are consistent with a previous report using Kavain significantly reduced inflammatory 
cell count,80.  Altogether the present data support a beneficial role of these 
compounds in reduction of inflammation. 
CONCLUSION 
 The distinct roles of 241, modified Kava compound to involve the 
pathogenesis of periodontitis and to the direct regulation of the inflammation were 
determined by using a P-gingivalis-induced mouse periodontitis model. The high 
correlation of inflammation vs. osteoclastogenesis, inflammation vs. periodontal 
tissue breakdown, and osteoclastogenesis vs. alveolar bone loss were confirmed. 
Administration of 241, modified Kava compound in periodontitis resulted in a 
reduction of periodontal breakdown, inflammatory cell infiltrate, osteoclastogenesis, 
and increase for fibroblasts. Results of this study demonstrate that in a murine model, 
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P. gingivalis induced periodontitis can be treated by 241. In addition, the 
experimental model demonstrated the use of morphometric and histomorphometric 
analyses to accurately quantify alveolar bone loss. Further modification of Kava 
could yield a more effective and safer therapeutic compound in the treatment of 
periodontal inflammation and bone loss. 
 
, 
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